1. Cell Therapy in Ischemic Heart Disease: Interventions That Modulate Cardiac Regeneration
    Maximiliano I. Schaun et al, 2016, Stem Cells International CrossRef
  2. Biomaterial strategies to improve the efficacy of bone marrow cell therapy for myocardial infarction
    Bora Nadlacki et al, 2016, Expert Opinion on Biological Therapy CrossRef
  3. Infantile Hemangiomas, Retinopathy of Prematurity and Cancer: A Common Pathogenetic Role of the β-Adrenergic System
    Luca Filippi et al, 2015, Med. Res. Rev. CrossRef
  4. Early and Late Histological and Ultrastructural Findings in Resected Infantile Capillary Hemangiomas Following Treatment with Topical Beta-Blocker Timolol Maleate 0.5%
    Zuzana Sipkova et al, 2018, Ocul Oncol Pathol CrossRef
  5. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment
    Jelena Petrovic et al, 2017, Journal of Dermatological Treatment CrossRef
  6. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol
    Anita Rotter et al, 2017, JDDG: Journal der Deutschen Dermatologischen Gesellschaft CrossRef
  7. Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol
    Anita Rotter et al, 2017, JDDG: Journal der Deutschen Dermatologischen Gesellschaft CrossRef
  8. Detection of p53 and Bcl-2 expression in cutaneous hemangioma through the quantum dot technique.
    Tian Tang et al, 2017, Oncol Lett CrossRef
  9. Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention
    Aeson Chang et al, 2015, Cancers CrossRef
  10. Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma
    Erin Dickerson et al, 2015, Veterinary Sciences CrossRef
  11. Bleeding risk of cerebral cavernous malformations in patients on β-blocker medication: a cohort study
    Johannes Goldberg et al, 2018, Journal of Neurosurgery CrossRef
  12. The Effect of β Receptor Blockade Through Propranolol on Corneal Neovascularization
    Hüseyin Simavli et al, 2014, Journal of Ocular Pharmacology and Therapeutics CrossRef
  13. Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET
    Diana C. Alcobia et al, 2018, iScience CrossRef
  14. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway
    Wei-Kang Pan et al, 2015, Pediatr Blood Cancer CrossRef
  15. null
    Scott R. Schoem, 2015 CrossRef
  16. Complex Formation between VEGFR2 and the β2-Adrenoceptor
    Laura E. Kilpatrick et al, 2019, Cell Chemical Biology CrossRef
  17. Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis
    Jina J.Y. Kum et al, 2014, Pediatr Res CrossRef
  18. null
    Francine Blei et al, 2015 CrossRef
    Sravani Polepalli et al, 2019, The International Journal of Biochemistry & Cell Biology CrossRef
  20. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
    Jessica M Stiles et al, 2013, PLoS ONE CrossRef
  21. Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age
    Paul Hong et al, 2013, International Journal of Pediatric Otorhinolaryngology CrossRef
  22. Late Rebound of Infantile Hemangioma after Cessation of Oral Propranolol
    Nancy Shehata et al, 2013, Pediatr Dermatol CrossRef
  23. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer
    Alexa Montoya et al, 2019, Biomedical Journal CrossRef
  24. Reply to Letter
    Harvey Chim, 2015, Annals of Surgery CrossRef
  25. Propranolol targets the contractility of infantile haemangioma-derived pericytes
    D. Lee et al, 2014, Br J Dermatol CrossRef
  26. Infantile haemangiomas that failed treatment with propranolol: Clinical and histopathological features
    Roderic J Phillips et al, 2014, J Paediatr Child Health CrossRef
  27. Current workup and therapy of infantile hemangiomas
    Francine Blei et al, 2014, Clinics in Dermatology CrossRef
  28. Glucose Transporter 1-Positive Endothelial Cells in Infantile Hemangioma Exhibit Features of Facultative Stem Cells
    Lan Huang et al, 2015, Stem Cells CrossRef
  29. Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol
    Ryan Steel et al, 2014, Pathology CrossRef
  30. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action
    Y. Ji et al, 2015, Br J Dermatol CrossRef
  31. Mechanisms of propranolol action in infantile hemangioma
    Jina JY Kum et al, 2014, Dermato-Endocrinology CrossRef
  32. Current trends in medical management of infantile hemangioma
    Julie A. Ames et al, 2015, Current Opinion in Otolaryngology & Head and Neck Surgery CrossRef
  33. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation
    Naikhoba C.O. Munabi et al, 2016 CrossRef
  34. Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage
    Joseph M. Zabramski et al, 2016, World Neurosurgery CrossRef
  35. β3-adrenoreceptor blockade reduces tumor growth and increases neuronal differentiation in neuroblastoma via SK2/S1P2 modulation
    Gennaro Bruno et al, 2019, Oncogene CrossRef
  36. Disorders of the neonatal nasal cavity: Fundamentals for practice
    Maheep Sohal et al, 2016, Seminars in Fetal and Neonatal Medicine CrossRef
  37. Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment
    Przemyslaw Przewratil et al, 2016, Immunology Letters CrossRef
  38. null
    Larissa Kerecuk et al, 2017 CrossRef
  39. Propranolol Attenuates Proangiogenic Activity of Mononuclear Phagocytes: Implication in Choroidal Neovascularization
    Samy Omri et al, 2019, Invest. Ophthalmol. Vis. Sci. CrossRef
  40. Surgical Intervention of Periocular Infantile Hemangiomas in the Era of β-Blockers
    Clara J. Men et al, 2020, Ophthalmic Plastic and Reconstructive Surgery CrossRef
  41. Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer
    Alexa Montoya et al, 2017, Oncotarget CrossRef
  42. Beta-adrenergic receptors are expressed across diverse cancers
    Steven L. Rains et al, 2017, Oncoscience CrossRef
  43. Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma
    Clarissa N. Amaya et al, 2018, Oncoscience CrossRef
  44. Combined effect of propranolol, vincristine and bevacizumab on HUVECs and BJ cells.
    Mădălina Bota et al, 2019, Exp Ther Med CrossRef
  45. NOTCH Pathway Activation in Infantile Hemangiomas
    Haihong Zhang et al, 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders CrossRef
  46. The expression and role of glycolysis-associated molecules in infantile hemangioma
    Jian Chen et al, 2020, Life Sciences CrossRef
  47. Beta-Blockers and Berberine: A Possible Dual Approach to Contrast Neuroblastoma Growth and Progression
    Maura Calvani et al, 2020, Oxidative Medicine and Cellular Longevity CrossRef
  48. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade
    François Moisan et al, 2021, Proc Natl Acad Sci USA CrossRef
  49. Infantile hemangiomas β3-adrenoceptor overexpression is associated with nonresponse to propranolol
    Andrea Bassi et al, 2021, Pediatr Res CrossRef
  50. Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta.
    James C Lee et al, 2021, Plast Reconstr Surg CrossRef
  51. A transcription factor is the target of propranolol treatment in infantile hemangioma
    Sandra Schrenk et al, 2022 CrossRef
  52. Nasal Obstruction in the Infant
    Samantha Frank et al, 2022, Pediatric Clinics of North America CrossRef
  53. Comparative Efficacy of Antihypertensive Agents in Flow-Mediated Vasodilation of Patients with Hypertension: Network Meta-Analysis of Randomized Controlled Trial
    Hong Ding et al, 2022, International Journal of Hypertension CrossRef
  54. VEGF Pathway Gene Expression Profile of Proliferating versus Involuting Infantile Hemangiomas: Preliminary Evidence and Review of the Literature
    Rodica Elena Heredea et al, 2022, Children CrossRef
  55. Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro
    Bruno Lorusso et al, 2022, Vascular Pharmacology CrossRef
  56. TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)—A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial
    Kornelia E. C. Andorfer et al, 2022, Pharmaceutics CrossRef
  57. R-Propranolol Has Broad-Spectrum Anti-Coronavirus Activity and Suppresses Factors Involved in Pathogenic Angiogenesis
    Melissa Thaler et al, 2023, IJMS CrossRef
  58. Ocular and orbital tumors in childhood
    Kathryn Bentivegna et al, 2024, Clinics in Dermatology CrossRef
  59. Infantile hemangioma: the common and enigmatic vascular tumor
    Annegret Holm et al, 2024 CrossRef